Emre Karaca
10 Numara!
- 27 Kasım 2008
- 14.586
- 2.266
- 1.778
marmarada küçük bir ildeyim
Koronavirüs Haberleri | Arşiv #2
- Konuyu Başlatan Keramettin TANRIVERDİ
- Başlangıç tarihi
- Durum
- 26 Kasım 2012
- 185.626
- 258.378
- 5.998
For 10 patients severely ill with the new coronavirus, a single dose of antibodies drawn from the blood of people who had recovered from COVID-19 appeared to save lives, shorten the duration of symptoms, improve oxygen levels and speed up viral clearance, newly published research reports.
The preliminary findings emerged from a “pilot study” published Monday in the journal PNAS, the Proceedings of the National Academies of Sciences. Conducted at three hospitals in China, it underscored the promise of harvesting immune antibodies from recovered people (a therapy also known as convalescent plasma) and administering them to people battling a severe case of COVID-19.
But its findings offer hope that a therapy with a long history and a simple premise could be a powerful treatment for COVID-19 patients fighting for breath. In the early 20th century, doctors transferred the bloodborne antibodies of patients who had recovered from polio, measles, mumps and flu to those who were in still in the grips of those infections. Armed with a veteran infectee's immune memory of the virus, patients getting convalescent plasma appeared to recover more quickly and completely than patients who did not get the treatment, physicians observed.
With a vaccine at least a year away and no clear treatments available for COVID-19, the U.S. Food and Drug Administration on Mar. 24 approved the use of such therapy as an experimental treatment in clinical trials and for critical patients without other options.
The new pilot study signaled that the therapy will not disappoint. One patient, a 46-year-old man with high blood pressure who showed up at a hospital with fever, cough, shortness of breath and chest pain, was relying on a ventilator to push oxygen into his lungs, and still his blood-oxygen level was a dismal 86%. (Normal readings range from 95% to 100%.)
Eleven days after his first symptoms had appeared, the patient received an infusion of so-called convalescent plasma. On day 12, his blood tested negative for infection with the SARS-CoV-2 virus. His body’s inflammation level turned sharply down. And his blood-oxygen level had climbed to 90%. The next day, he was weaned off of the mechanical ventilation that had breathed for him for three days.
In addition to his lungs, the patient’s immune system and liver function, both on the ropes at the height of his illness, were steadily returning to normal four days after he got the plasma antibody infusion.
For a 49-year-old woman with no underlying illnesses, COVID-19 infection quickly progressed to shortness of breath and hospital admission. By day seven after the onset of her symptoms, her chest X-ray had shown the hallmark opacity of ground glass and she had build-ups of fluids or proteins — infiltrates — scattered throughout both lungs. On day 10 following the onset of symptoms, she got an infusion of convalescent plasma. By day 12, she had cleared the virus from her system and her chest X-ray was clearing markedly.
A 50-year-old male with “massive infiltrates” in both lungs showed a gradual clearing of his lungs and tested negative for infection 25 days after his first symptoms appeared.
In all ten patients, the symptoms that had driven them to seek emergency care had either disappeared or largely improved within one to three days of their receiving a transfusion of antibodies from a recovered donor. Two of the three patients who had been breathing with the help of a mechanical ventilator were able to step down to oxygen delivered into the nose.
None of the 10 patients died, and only one unexpected side effect — a red bruise on one patient’s face — was detected.
The study was not designed to have a comparison group of patients that got no convalescent plasma. But the authors did create a control group from a random selection of 10 COVID-19 patients treated in the same hospitals and matched to the ten study participants in age and gender and the illness severity.
The two groups looked roughly the same on day one of their admissions to the hospital. But over the next several weeks, their illnesses progressed in sharply different ways. In the comparison group, three died, six saw their conditions stabilize, and one got better during the study period.
Of those who received convalescent plasma, three were discharged from the hospital, and the remaining seven were rated “much improved” and ready for discharge.
“This pilot study on [convalescent plasma] therapy shows a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients,” the authors of the new research wrote. “One dose of [convalescent plasma] with a high concentration of neutralizing antibodies can rapidly reduce the viral load and tends to improve clinical outcomes,” they added.
The authors, led by Kai Duan of China's National Biotec Group Co. Ltd., said that only larger and more detailed studies will clarify the dose at which convalescent plasma produces the most healing effects, and when it should ideally be administered.
In recent days, the New York Blood Center (NYBC) has issued an urgent appeal for recovered COVID-19 patients to donate blood plasma for the creation of antibody-rich infusions. The first state blood bank to become a central repository for convalescent plasma, NYBC will collect, process the plasma for infusion, and maintain a bank for hospitals to treat patients with serious or immediately life-threatening COVID-19 infections.
Operating under guidelines released last week by the American Assn. of Blood Banks, an international nonprofit agency focused on transfusion medicine and cellular therapies, dozens of community blood centers nationwide have also begun gathering blood to create such treatments.
The Mayo Clinic in Rochester, Minn., also has launched a small trial of convalescent plasma as a means of reducing COVID-19 complications.
The preliminary findings emerged from a “pilot study” published Monday in the journal PNAS, the Proceedings of the National Academies of Sciences. Conducted at three hospitals in China, it underscored the promise of harvesting immune antibodies from recovered people (a therapy also known as convalescent plasma) and administering them to people battling a severe case of COVID-19.
But its findings offer hope that a therapy with a long history and a simple premise could be a powerful treatment for COVID-19 patients fighting for breath. In the early 20th century, doctors transferred the bloodborne antibodies of patients who had recovered from polio, measles, mumps and flu to those who were in still in the grips of those infections. Armed with a veteran infectee's immune memory of the virus, patients getting convalescent plasma appeared to recover more quickly and completely than patients who did not get the treatment, physicians observed.
With a vaccine at least a year away and no clear treatments available for COVID-19, the U.S. Food and Drug Administration on Mar. 24 approved the use of such therapy as an experimental treatment in clinical trials and for critical patients without other options.
The new pilot study signaled that the therapy will not disappoint. One patient, a 46-year-old man with high blood pressure who showed up at a hospital with fever, cough, shortness of breath and chest pain, was relying on a ventilator to push oxygen into his lungs, and still his blood-oxygen level was a dismal 86%. (Normal readings range from 95% to 100%.)
Eleven days after his first symptoms had appeared, the patient received an infusion of so-called convalescent plasma. On day 12, his blood tested negative for infection with the SARS-CoV-2 virus. His body’s inflammation level turned sharply down. And his blood-oxygen level had climbed to 90%. The next day, he was weaned off of the mechanical ventilation that had breathed for him for three days.
In addition to his lungs, the patient’s immune system and liver function, both on the ropes at the height of his illness, were steadily returning to normal four days after he got the plasma antibody infusion.
For a 49-year-old woman with no underlying illnesses, COVID-19 infection quickly progressed to shortness of breath and hospital admission. By day seven after the onset of her symptoms, her chest X-ray had shown the hallmark opacity of ground glass and she had build-ups of fluids or proteins — infiltrates — scattered throughout both lungs. On day 10 following the onset of symptoms, she got an infusion of convalescent plasma. By day 12, she had cleared the virus from her system and her chest X-ray was clearing markedly.
A 50-year-old male with “massive infiltrates” in both lungs showed a gradual clearing of his lungs and tested negative for infection 25 days after his first symptoms appeared.
In all ten patients, the symptoms that had driven them to seek emergency care had either disappeared or largely improved within one to three days of their receiving a transfusion of antibodies from a recovered donor. Two of the three patients who had been breathing with the help of a mechanical ventilator were able to step down to oxygen delivered into the nose.
None of the 10 patients died, and only one unexpected side effect — a red bruise on one patient’s face — was detected.
The study was not designed to have a comparison group of patients that got no convalescent plasma. But the authors did create a control group from a random selection of 10 COVID-19 patients treated in the same hospitals and matched to the ten study participants in age and gender and the illness severity.
The two groups looked roughly the same on day one of their admissions to the hospital. But over the next several weeks, their illnesses progressed in sharply different ways. In the comparison group, three died, six saw their conditions stabilize, and one got better during the study period.
Of those who received convalescent plasma, three were discharged from the hospital, and the remaining seven were rated “much improved” and ready for discharge.
“This pilot study on [convalescent plasma] therapy shows a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients,” the authors of the new research wrote. “One dose of [convalescent plasma] with a high concentration of neutralizing antibodies can rapidly reduce the viral load and tends to improve clinical outcomes,” they added.
The authors, led by Kai Duan of China's National Biotec Group Co. Ltd., said that only larger and more detailed studies will clarify the dose at which convalescent plasma produces the most healing effects, and when it should ideally be administered.
In recent days, the New York Blood Center (NYBC) has issued an urgent appeal for recovered COVID-19 patients to donate blood plasma for the creation of antibody-rich infusions. The first state blood bank to become a central repository for convalescent plasma, NYBC will collect, process the plasma for infusion, and maintain a bank for hospitals to treat patients with serious or immediately life-threatening COVID-19 infections.
Operating under guidelines released last week by the American Assn. of Blood Banks, an international nonprofit agency focused on transfusion medicine and cellular therapies, dozens of community blood centers nationwide have also begun gathering blood to create such treatments.
The Mayo Clinic in Rochester, Minn., also has launched a small trial of convalescent plasma as a means of reducing COVID-19 complications.
- 18 Temmuz 2009
- 82.258
- 240.493
- 5.263
Yarro mu, küfür iması ha.
- 23 Temmuz 2011
- 75.742
- 51.226
- 4.843
- 18 Temmuz 2009
- 82.258
- 240.493
- 5.263
Durumun gösterilenden daha kötü olduğu çok bariz. Sağlık sektöründe işin içinde olan kimse sorsam kötümser bakıyor.
Zamanında vaka sayısı 20yken bir doktor "vaka binleri buldu." dediğinde; doğru olan doktorun dediğiydi, resmi rakam değil.
Konuyu politikaya çeviren kimseyi de göremiyorum. Neyse.
Zamanında vaka sayısı 20yken bir doktor "vaka binleri buldu." dediğinde; doğru olan doktorun dediğiydi, resmi rakam değil.
Konuyu politikaya çeviren kimseyi de göremiyorum. Neyse.
- 23 Temmuz 2011
- 75.742
- 51.226
- 4.843
yazık o doktordan özür dilettiler, açıklama yapmak zorunda kaldı.
- 26 Kasım 2008
- 18.139
- 17.027
- 2.443
Can Karabacak
Ulubatlı Souness
- 2 Ağustos 2018
- 33.103
- 21.222
- 1.568
Emrah Duvar
Taçsız Kral
- 5 Ocak 2011
- 115.242
- 102.357
- 5.238
Ağzına layık
Can Karabacak
Ulubatlı Souness
- 2 Ağustos 2018
- 33.103
- 21.222
- 1.568
domfzero
Ibrahim Özveren
10 Numara!
- 26 Ağustos 2018
- 15.168
- 13.795
- 1.098
Bağışla adminim. Evde karantina altinda kala kala hepimize bir haller oluyor. Biraz heyecan katalim dedik foruma
Can Karabacak
Ulubatlı Souness
- 2 Ağustos 2018
- 33.103
- 21.222
- 1.568
aytac yalmanin esi de covidden vefad etmiş
- 26 Kasım 2012
- 185.626
- 258.378
- 5.998
Sağlık Bakanlığı Bilim Kurulu üyesi Prof. Dr. Levent Yamanel, “Tedbirlere riayet ettiğimiz zaman iki-üç hafta içerisinde bir kırılma noktası göreceğiz ve bu pik yatay bir plato çizmeye başlayacak” dedi.
Prof. Dr. Yamanel, kurulun salgınla mücadele kapsamında aldığı tedbirlerin sonucunun yaklaşık üç hafta sonunda görüleceğini hatırlatarak şunları söyledi: “Bu iki-üç haftada bu piki kırabilecek miyiz çok önemli. Eğer biz kurallara uyarsak iki-üç haftada o kritik eşiğe gelir, kırılmayı sağlayabilirsek, yani o yükselmeden sonraki platoya dönme eşiğini yakalayabilirsek o zaman biz ülkece başarmış olacağız. Ve böylece de iki-üç ay içerisinde de virüsü kontrol altına alma ihtimalimiz olacak”.
Salgının pik noktasına ulaşmasından sonra günlük hayatın hemen normale dönmesinin mümkün olmadığının altını çizen Prof. Dr. Yamanel, “Bazı ülkelerde bu kırılma noktasını gördüler ve önlemleri gevşetince ikinci pik olmaya başladı. O yüzden çok dikkatli olmamız lazım. Kontrollü bir şekilde günlük hayata geçeceğiz” dedi.
Prof.Dr. Yamanel, hastalığın kişiden kişiye damlacık yoluyla bulaştığını hatırlatrak şu uyarıları yaptı: “Eğer konuşurken siz 10-15 dakika bir metreden fazla yanaşıyorsanız karşıya bulaştırabiliyorsunuz. Ağzını kapatmıyorsanız öksürmeyle veya hapşırmayla karşıya bulaştırabiliyorsunuz. Bu nedenle özellikle tek kullanımlık mendille, öksürürken hapşırırken ağzımızı kapatmak çok önemli bir şey, eğer elimizde tek kullanımlık mendil yoksa o zaman dirsek içini kullanıyoruz. Çok şiddetli bir hapşırmayla mesela damlacığın 8 metre yayıldığını biliyoruz”.
Prof. Dr. Yamanel, kurulun salgınla mücadele kapsamında aldığı tedbirlerin sonucunun yaklaşık üç hafta sonunda görüleceğini hatırlatarak şunları söyledi: “Bu iki-üç haftada bu piki kırabilecek miyiz çok önemli. Eğer biz kurallara uyarsak iki-üç haftada o kritik eşiğe gelir, kırılmayı sağlayabilirsek, yani o yükselmeden sonraki platoya dönme eşiğini yakalayabilirsek o zaman biz ülkece başarmış olacağız. Ve böylece de iki-üç ay içerisinde de virüsü kontrol altına alma ihtimalimiz olacak”.
Salgının pik noktasına ulaşmasından sonra günlük hayatın hemen normale dönmesinin mümkün olmadığının altını çizen Prof. Dr. Yamanel, “Bazı ülkelerde bu kırılma noktasını gördüler ve önlemleri gevşetince ikinci pik olmaya başladı. O yüzden çok dikkatli olmamız lazım. Kontrollü bir şekilde günlük hayata geçeceğiz” dedi.
Prof.Dr. Yamanel, hastalığın kişiden kişiye damlacık yoluyla bulaştığını hatırlatrak şu uyarıları yaptı: “Eğer konuşurken siz 10-15 dakika bir metreden fazla yanaşıyorsanız karşıya bulaştırabiliyorsunuz. Ağzını kapatmıyorsanız öksürmeyle veya hapşırmayla karşıya bulaştırabiliyorsunuz. Bu nedenle özellikle tek kullanımlık mendille, öksürürken hapşırırken ağzımızı kapatmak çok önemli bir şey, eğer elimizde tek kullanımlık mendil yoksa o zaman dirsek içini kullanıyoruz. Çok şiddetli bir hapşırmayla mesela damlacığın 8 metre yayıldığını biliyoruz”.
- 29 Haziran 2015
- 34.736
- 28.299
- 2.083
Ve böylece de iki-üç ay içerisinde de virüsü kontrol altına alma ihtimalimiz olacak
Abow
Abow
- 15 Eylül 2009
- 65.319
- 11.748
- 2.993
son 24 saatte 2 bine yakin insan ölmüs amerikada.
durum cok kötü orada.
Gesendet von meinem SM-G965F mit Tapatalk
durum cok kötü orada.
Gesendet von meinem SM-G965F mit Tapatalk
Halim Kırıkçı
Şef Gümüş Kıvrım
- 12 Ocak 2011
- 75.210
- 39.469
- 3.993
2 3 hafta vs rakamlarina çok takılmayın artık 1 aydır sürekli söyleniyor bu rakamlar drlarda virüsü çok tanımıyor tanınmadığı için virüsün kendi kendine etkisi düşsün diye bekleniyor o yüzden söylemler var.
- 26 Ocak 2013
- 24.977
- 16.603
- 1.768
2-3 aya kontrol altına almak mı?
Rıfkı Karakülah
Ulubatlı Souness
- 8 Aralık 2008
- 35.654
- 10.258
- 2.168
- 15 Eylül 2009
- 65.319
- 11.748
- 2.993
dün gece alman haberlerini izlerken beynim yandi.
82 milyon nüfuslu almanyanin yüzde 60ina coronayi bulastirip bagisiklik kazanmanlarini bekleyebiliriz gibi bir fikir paylasildi. eger ters teperse 10 milyon insana yakin ölebilir ama virüsü yenmis oluruz diyordu bir profesör.
Gesendet von meinem SM-G965F mit Tapatalk
82 milyon nüfuslu almanyanin yüzde 60ina coronayi bulastirip bagisiklik kazanmanlarini bekleyebiliriz gibi bir fikir paylasildi. eger ters teperse 10 milyon insana yakin ölebilir ama virüsü yenmis oluruz diyordu bir profesör.
Gesendet von meinem SM-G965F mit Tapatalk
Rıfkı Karakülah
Ulubatlı Souness
- 8 Aralık 2008
- 35.654
- 10.258
- 2.168
- Durum